Femasys Inc (FEMY) USD0.001

Sell:$0.81Buy:$0.83$0.03 (3.61%)

Prices delayed by at least 15 minutes
Sell:$0.81
Buy:$0.83
Change:$0.03 (3.61%)
Prices delayed by at least 15 minutes
Sell:$0.81
Buy:$0.83
Change:$0.03 (3.61%)
Prices delayed by at least 15 minutes

Company Information

About this company

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

Key people

Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
Dov Elefant
Chief Financial Officer
Daniel Currie
Chief Operating Officer
James H. Liu
Chief Medical Officer
Christine Thomas
Chief Regulatory and Clinical Officer
Charles E. Larsen
Non-Executive Independent Chairman of the Board
Alistair Milnes
Independent Director
Joshua N. Silverman
Independent Director
Edward Uzialko
Independent Director
Click to see more

Key facts

  • EPIC
    FEMY
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US31447E1055
  • Market cap
    $22.61m
  • Employees
    69
  • Shares in issue
    32.49m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.